Volume 32, No 1, Jan 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 1, January 2022: 107-109   |  Open Access

LETTERS TO THE EDITOR

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine

Yunlong Cao^1,2,3,†,* , Xiaohua Hao^4,† , Xi Wang^4,5,† , Qianhui Wu^6,† , Rui Song⁴ , Dong Zhao⁴ , Weiliang Song^2,7 , Yao Wang^1,2 , Ayijiang Yisimayi^2,7 , Wei Wang^4,6 , Juan Du^{1,2,3,4,5,6,7,8,9} , Hongjie Yu^6,8,9,* , Xiaoliang Sunney Xie^1,2,3,7,* , Ronghua Jin^1,4,5,*

¹Changping Laboratory, Beijing, China
²Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China
³Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China
⁴National Center For Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
⁵Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
⁶School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
⁷School of Life Sciences, Peking University, Beijing, China
⁸Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
⁹Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
^†These authors contributed equally: Yunlong Cao, Xiaohua Hao, Xi Wang, Qianhui Wu
Correspondence: Yunlong Cao(yunlongcao@pku.edu.cn)Hongjie Yu(yhj@fudan.edu.cn)Xiaoliang Sunney Xie(sunneyxie@biopic.pku.edu.cn)Ronghua Jin(ronghuajin@ccmu.edu.cn)

Dear Editor,

COVID-19 vaccination campaigns are being conducted in countries worldwide, and 47.4% of the world population has received at least one dose of a COVID-19 vaccine.1 Although vaccination has shaped COVID-19 epidemic curves, waning antibody levels and relatively short-duration protection provided by current COVID-19 vaccines have been observed, especially against SARS-CoV-2 variants of concern (VOCs) and among older individuals.2 Booster dose programs have been started in nearly 50 countries, and preliminary evaluation shows that the additional doses reduce breakthrough infections and numbers of symptomatic cases.1,3 The World Health Organization now recommends that for Sinovac and Sinopharm inactivated vaccines, immunization programs should offer an additional (third) dose of the homologous vaccine for people 60 years and older as part of an extended primary series, and that heterologous platforms vaccine for the additional dose may also be considered based on vaccine supply and access considerations. Interim results from heterologous prime-boost studies showed that boosting with heterologous platform vaccines could induce significantly higher titers of neutralizing antibodies and better cellular immunity, providing evidence for programmatic consideration of an alternative to homologous boosting.4

https://doi.org/10.1038/s41422-021-00596-5

FULL TEXT | PDF

Browse 992